Efficacy and safety of ruxolitinib cream for the treatment of moderate to severe chronic hand eczema: Results from a 16-week, multicenter, randomized, double-blind study
Ruxolitinib cream represents an effective treatment option for nonatopic CHE subtypes that are not controlled with standard therapies.
Authors
- Matthew Zirwas
- Linda Stein Gold (ORCID: https://orcid.org/0000-0002-2758-1605)
- Zhihong Lai (ORCID: https://orcid.org/0000-0001-6475-4360)
- Athanasios Tsianakas (ORCID: https://orcid.org/0000-0003-1563-7402)
- Alim R Devani
- Philippa Halden
- Haq Nawaz (ORCID: https://orcid.org/0000-0001-8888-4733)
- YuTzu Kuo
- Joseph F. Fowler
Institutions
- University of Louisville (US)
- Henry Ford Health System (US)
- Ohio University (US)
- Incyte (United States) (US)
Publication Details
- Journal
- Journal of the American Academy of Dermatology
- Published
- 2025-08-30
- DOI
- https://doi.org/10.1016/j.jaad.2025.08.081
- Citations
- 6
- Primary Topic
- Contact Dermatitis and Allergies
- Type
- article
- Field-Weighted Citation Impact
- 12.03